Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma

Journal of Clinical Investigation

Volumn 121, Issue 5, 2011, Pages 1797-1809

  Byrne, Katelyn T ^a   Côté, Anik L ^a   Zhang, Peisheng ^a   Steinberg, Shannon M ^a   Guo, Yanxia ^a   Allie, Rameeza ^a   Zhang, Weijun ^a   Ernstoff, Marc S ^b   Usherwood, Edward J ^a   Turk, Mary Jo ^a,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; MALE; MELANOCYTE; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VITILIGO;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOMEOSTASIS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SKIN NEOPLASMS; VITILIGO;

EID: 79955509612     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44849     Document Type: Article

References (56)

1. Cote AL, Usherwood EJ, Turk MJ. Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res. 2008;68(6):1614-1617. (Pubitemid 351416543)
2. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224. (Pubitemid 43882974)
3. Gattinoni L, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808-813.
4. Klebanoff CA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102(27):9571-9576. (Pubitemid 40981722)
5. Zhang P, Cote AL, de Vries VC, Usherwood EJ, Turk MJ. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 2007;67(13):6468-6476. (Pubitemid 47037532)
6. Grosso JF, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007; 117(11):3383-3392. (Pubitemid 350096994)
7. Turner MJ, Jellison ER, Lingenheld EG, Puddington L, Lefrancois L. Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J Exp Med. 2008;205(8):1859-1868.
8. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22(2):223-230.
9. Quaglino P, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21(2):409-414.
10. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987;123(8):1053-1055. (Pubitemid 17134848)
11. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9(5):689-696. (Pubitemid 14230566)
12. Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709-718. (Pubitemid 43247141)
13. Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372-8377. (Pubitemid 36842552)
14. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
15. Le Gal FA, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001;117(6):1464-1470.
16. Jacobs JF, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother. 2009; 58(1):145-151.
17. Uchi H, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol. 2006; 90:215-241. (Pubitemid 43765798)
18. Lengagne R, et al. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res. 2004;64(4):1496-1501. (Pubitemid 38235622)
19. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004;200(6):771-782. (Pubitemid 39299463)
20. Engelhorn ME, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med. 2006;12(2):198-206. (Pubitemid 43214746)
21. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accom panied by autoimmune depigmentation. J Exp Med. 1999;190(3):355-366. (Pubitemid 29374833)
22. Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte- macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol. 2005; 175(3):1456-1463. (Pubitemid 41023045)
23. Overwijk WW, et al. Tumor regression and auto-immunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198(4):569-580. (Pubitemid 37040391)
24. Cable J, Jackson IJ, Steel KP. Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Dev. 1995;50(2-3):139- 150.
25. Schreurs MW, de Boer AJ, Schmidt A, Figdor CG, Adema GJ. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res. 1997; 7(6):463-470.
26. Brouwenstijn N, et al. Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer. 1997;76(12):1562-1566. (Pubitemid 27520582)
27. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007;13(10):1211-1218. (Pubitemid 47530639)
28. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol. 2005; 167(3):835-848. (Pubitemid 41216366)
29. Perales MA, et al. GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther. 2002;7(3):125-133.
30. Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infection. Curr Opin Immunol. 2007;19(4):408-415. (Pubitemid 47284857)
31. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911-4927. (Pubitemid 36402840)
32. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009; 10(1):29-37.
33. Goldman L, Wilson RG, Glasgow R, Richfield R. Perilesional leucoderma in metastatic melanoma. The use of the Wood's light for early detection of this rare reaction. Acta Derm Venereol. 1967;47(5):369-372.
34. Burdick KH, Hawk WA. Vitiligo in a case of vaccinia virus-treated melanoma. Cancer. 1964;17:708-712.
35. Lengagne R, et al. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol. 2008;180(1):130-137.
36. Daniels GA, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol. 2004;22(9):1125-1132. (Pubitemid 39166850)
37. Sanchez-Perez L, et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol. 2006;177(6):4168-4177.
38. van den Boorn JG, et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One. 2010;5(5):e10626.
39. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A. 2004;101(45):16004-16009.
40. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol. 2004;172(10):6074-6079.
41. Evans AG, Moser JM, Krug LT, Pozharskaya V, Mora AL, Speck SH. A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology. J Exp Med. 2008; 205(3):669-684. (Pubitemid 351439312)
42. Obar JJ, Fuse S, Leung EK, Bellfy SC, Usherwood EJ. Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol. 2006;80(17):8303-8315. (Pubitemid 44384844)
43. Cush SS, Anderson KM, Ravneberg DH, Weslow-Schmidt JL, Flano E. Memory generation and maintenance of CD8+ T cell function during viral persistence. J Immunol. 2007;179(1):141-153. (Pubitemid 46986528)
44. Martin DL, Tarleton RL. Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol. 2005;174(3):1594-1601.
45. Daniels MA, Teixeiro E. The persistence of T cell memory. Cell Mol Life Sci. 2010;67(17):2863-2878.
46. Itsumi M, Yoshikai Y, Yamada H. IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells. Eur J Immunol. 2009; 39(7):1784-1793.
47. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528-1536.
48. Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-1544.
49. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-687. (Pubitemid 43237609)
50. Frank GM, Lepisto AJ, Freeman ML, Sheridan BS, Cherpes TL, Hendricks RL. Early CD4(+) T cell help prevents partial CD8(+) T cell exhaustion and promotes maintenance of Herpes Simplex Virus 1 latency. J Immunol. 2010;184(1):277-286.
51. Perret R, Ronchese F. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens. 2008;72(3):187-194.
52. Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood. 2009; 114(9):1776-1783.
53. Walker EB, et al. Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res. 2008;14(16):5270-5283.
54. Jin Y, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med. 2010;362(18):1686-1697.
55. Lerner AB, Nordlund JJ. Should vitiligo be induced in patients after resection of primary melanoma. Arch Dermatol. 1977;113(4):421. (Pubitemid 8071599)
56. Scheibenbogen C, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer. 1997;71(6):932-936. (Pubitemid 27252870)